163 related articles for article (PubMed ID: 25595173)
1. Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients.
Sheng X; Li S; Chi Z; Si L; Cui C; Mao L; Lian B; Tang B; Wang X; Yan X; Kong Y; Dai J; Guo J
Br J Ophthalmol; 2015 Jul; 99(7):990-6. PubMed ID: 25595173
[TBL] [Abstract][Full Text] [Related]
2. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
Larsen AC
Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Review of Conjunctival Melanoma Presentation, Treatment, and Outcome and an Investigation of Features Associated With BRAF Mutations.
Larsen AC; Dahmcke CM; Dahl C; Siersma VD; Toft PB; Coupland SE; Prause JU; Guldberg P; Heegaard S
JAMA Ophthalmol; 2015 Nov; 133(11):1295-303. PubMed ID: 26425792
[TBL] [Abstract][Full Text] [Related]
4. Conjunctival Melanoma: Current Treatments and Future Options.
Grimes JM; Shah NV; Samie FH; Carvajal RD; Marr BP
Am J Clin Dermatol; 2020 Jun; 21(3):371-381. PubMed ID: 31965542
[TBL] [Abstract][Full Text] [Related]
5. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
6. BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma.
Wolfe AR; Chablani P; Siedow MR; Miller ED; Walston S; Kendra KL; Wuthrick E; Williams TM
Radiat Oncol; 2021 Sep; 16(1):181. PubMed ID: 34537078
[TBL] [Abstract][Full Text] [Related]
7. Conjunctival Melanoma in Chinese Patients: Local Recurrence, Metastasis, Mortality, and Comparisons With Caucasian Patients.
Zhou C; Wang Y; Jia R; Fan X
Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5452-5459. PubMed ID: 29059312
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
Roth AD; Delorenzi M; Tejpar S; Yan P; Klingbiel D; Fiocca R; d'Ario G; Cisar L; Labianca R; Cunningham D; Nordlinger B; Bosman F; Van Cutsem E
J Natl Cancer Inst; 2012 Nov; 104(21):1635-46. PubMed ID: 23104212
[TBL] [Abstract][Full Text] [Related]
9. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
11. [Adjuvant therapy and interdisciplinary follow-up care of conjunctival melanoma].
Heindl LM; Koch KR; Schlaak M; Mauch C; Cursiefen C
Ophthalmologe; 2015 Nov; 112(11):907-11. PubMed ID: 26502167
[TBL] [Abstract][Full Text] [Related]
12. Greater Tumor Thickness, Ulceration, and Positive Sentinel Lymph Node Are Associated With Worse Prognosis in Patients With Conjunctival Melanoma: Implications for Future AJCC Classifications.
Esmaeli B; Rubin ML; Xu S; Goepfert RP; Curry JL; Prieto VG; Ning J; Tetzlaff MT
Am J Surg Pathol; 2019 Dec; 43(12):1701-1710. PubMed ID: 31425167
[TBL] [Abstract][Full Text] [Related]
13. Conjunctival melanoma treatment outcomes in 288 patients: a multicentre international data-sharing study.
Jain P; Finger PT; Fili M; Damato B; Coupland SE; Heimann H; Kenawy N; J Brouwer N; Marinkovic M; Van Duinen SG; Caujolle JP; Maschi C; Seregard S; Pelayes D; Folgar M; Yousef YA; Krema H; Gallie B; Calle-Vasquez A;
Br J Ophthalmol; 2021 Oct; 105(10):1358-1364. PubMed ID: 32892167
[TBL] [Abstract][Full Text] [Related]
14. [Treatment modalities for conjunctival melanoma].
Krause L; Mladenova A; Bechrakis NE; Kreusel KM; Plath T; Moser L; Foerster M
Klin Monbl Augenheilkd; 2009 Dec; 226(12):1012-6. PubMed ID: 20108195
[TBL] [Abstract][Full Text] [Related]
15. Mucosal malignant melanoma - a clinical, oncological, pathological and genetic survey.
Mikkelsen LH; Larsen AC; von Buchwald C; Drzewiecki KT; Prause JU; Heegaard S
APMIS; 2016 Jun; 124(6):475-86. PubMed ID: 27004972
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Corrie PG; Marshall A; Nathan PD; Lorigan P; Gore M; Tahir S; Faust G; Kelly CG; Marples M; Danson SJ; Marshall E; Houston SJ; Board RE; Waterston AM; Nobes JP; Harries M; Kumar S; Goodman A; Dalgleish A; Martin-Clavijo A; Westwell S; Casasola R; Chao D; Maraveyas A; Patel PM; Ottensmeier CH; Farrugia D; Humphreys A; Eccles B; Young G; Barker EO; Harman C; Weiss M; Myers KA; Chhabra A; Rodwell SH; Dunn JA; Middleton MR; ; Nathan P; Lorigan P; Dziewulski P; Holikova S; Panwar U; Tahir S; Faust G; Thomas A; Corrie P; Sirohi B; Kelly C; Middleton M; Marples M; Danson S; Lester J; Marshall E; Ajaz M; Houston S; Board R; Eaton D; Waterston A; Nobes J; Loo S; Gray G; Stubbings H; Gore M; Harries M; Kumar S; Goodman A; Dalgleish A; Martin-Clavijo A; Marsden J; Westwell S; Casasola R; Chao D; Maraveyas A; Marshall E; Patel P; Ottensmeier C; Farrugia D; Humphreys A; Eccles B; Dega R; Herbert C; Price C; Brunt M; Scott-Brown M; Hamilton J; Hayward RL; Smyth J; Woodings P; Nayak N; Burrows L; Wolstenholme V; Wagstaff J; Nicolson M; Wilson A; Barlow C; Scrase C; Podd T; Gonzalez M; Stewart J; Highley M; Wolstenholme V; Grumett S; Goodman A; Talbot T; Nathan K; Coltart R; Gee B; Gore M; Farrugia D; Martin-Clavijo A; Marsden J; Price C; Farrugia D; Nathan K; Coltart R; Nathan K; Coltart R
Ann Oncol; 2018 Aug; 29(8):1843-1852. PubMed ID: 30010756
[TBL] [Abstract][Full Text] [Related]
17. Late Solitary Extraocular Recurrence From Previously Resected Iris Melanoma.
Fabian ID; Thaung C; AlHarby L; Sisley K; Mudhar HS; Doherty RE; Stacey AW; Arora AK; Cohen VML; Sagoo MS
Am J Ophthalmol; 2017 Sep; 181():97-105. PubMed ID: 28673748
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.
Li T; Jia DD; Teng LS
Invest New Drugs; 2020 Oct; 38(5):1334-1341. PubMed ID: 32072356
[TBL] [Abstract][Full Text] [Related]
19. KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas.
Dias-Santagata D; Selim MA; Su Y; Peng Y; Vollmer R; Chłopik A; Tell-Marti G; Paral KM; Shalin SC; Shea CR; Puig S; Fernandez-Figueras MT; Biernat W; Ryś J; Marszalek A; Hoang MP
Br J Dermatol; 2017 Nov; 177(5):1376-1384. PubMed ID: 28734009
[TBL] [Abstract][Full Text] [Related]
20. NF1 mutations in conjunctival melanoma.
Scholz SL; Cosgarea I; Süßkind D; Murali R; Möller I; Reis H; Leonardelli S; Schilling B; Schimming T; Hadaschik E; Franklin C; Paschen A; Sucker A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Br J Cancer; 2018 May; 118(9):1243-1247. PubMed ID: 29559732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
